Home › New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
 

Keywords :   


New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer

2015-09-08 07:25:25| drugdiscoveryonline Home Page

Bristol-Myers Squibb Company recently announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC)

Tags: with advanced cell treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »